investors.bmrn.comInvestor Relations : BioMarin

Clinical Trials Contact Us Careers -- Our Motivation Patient Stories Bailey Kendra Sheri Matty Diseases & Conditions PKU CLN2 Disease MPS VI MPS IVA MPS I Patient & Community Support RARE Scholars In the Hemophilia Community Patient Advocacy BioMarin RareConnections™ Funding & Support Resource Library Patient Organizations Professional Organizations Our Treatments Our Products PALYNZIQ ® (pegvaliase-pqpz) Injection for PKU Brineura ® (cerliponase alfa) for CLN2 Disease Vimizim ® (elosulfase alfa) for Morquio A Syndrome (MPS IVA) Kuvan ® (sapropterin dihydrochloride) for PKU Aldurazyme ® (laronidase) for MPS I Naglazyme ® (galsulfase) for MPS VI Our Pipeline Valoctocogene Roxaparvovec for Severe Hemophilia A Vosoritide for Achondroplasia BMN 307 for Phenylketonuria (PKU) BMN 331 for Hereditary Angiodema (HAE) Our Company About Us Our History Manufacturing Excellence Message from Chairman and CEO Diversity & Inclusion Global Compliance & Ethics Corporate Global Responsibility Leadership Team Jean-Jacques Bienaimé Robert A. Baffi, Ph.D. Henry J. Fuchs, M.D. Jeff Ajer G. Eric Davis Dr. C. Greg Guyer Ph.D. Amy Wireman Dr. Brinda Balakrishnan, M.D., Ph.D. Lon Cardon, Ph.D. Brian R. Mueller Board of Directors Funding & Support Grants & Donations Publication Data Request Independent Medical Education Independent Research Investors & Media Welcome to BioMarin's Investor Relations & Media Page Press Releases Events & Presentations Corporate Governance Management Board of Directors Committee Composition Contact the Board Financial Information SEC Filings Annual Reports Quarterly Results IR Key Ratios Financial Statements BioMarin UK Tax Strategy Analyst Coverage Stock Information Historical Stock Lookup Investor FAQs Contact Us Email Alerts Search Search Our Motivation Patient Stories Diseases & Conditions Patient & Community Support Resources Our Treatments Our Products PALYNZIQ® (pegvaliase-pqpz) Injection for PKU Kuvan® (sapropterin dihydrochloride) for PKU Brineura® (cerliponase alfa) for CLN2 Disease Aldurazyme® (laronidase) for MPS I Vimizim® (elosulfase alfa) for Morquio A Syndrome (MPS IVA) Naglazyme® (galsulfase) for MPS VI Our Pipeline BMN 307 for Phenylketonuria (PKU) BMN 331 for Hereditary Angiodema (HAE) Valoctocogene Roxaparvovec for Severe Hemophilia A Vosoritide for Achondroplasia Compassionate Use Policy Our Company About Us Corporate Global Responsibility Leadership Team Board of Directors Funding & Support Investors & Media Welcome to BioMarin's Investor Relations & Media Page Press Releases Events & Presentations Corporate Governance Management Board of Directors Committee Composition Contact the Board Financial Information SEC Filings Annual Reports Quarterly Results IR Key Ratios Financial Statements BioMarin UK Tax Strategy Analyst Coverage Stock Information Historical Stock Lookup Investor FAQs Contact Us Email Alerts Privacy Policy LinkedIn Terms of Use Facebook Site Map Instagram Supplier Information YouTube Glossary © 2020 BioMarin. All rights reserved. Investors & Media Our Company About Us Our History Message from Chairman and CEO Manufacturing Excellence Diversity & Inclusion Global Compliance & Ethics Corporate Global Responsibility Leadership Team Jean-Jacques Bienaimé Robert A. Baffi, Ph.D. Henry J. Fuchs, M.D. Jeff Ajer G. Eric Davis Philip Lo Scalzo Amy Wireman Dr. Brinda Balakrishnan, M.D., Ph.D. Lon Cardon, Ph.D. Brian R. Mueller Dr. C. Greg Guyer Ph.D. Board of Directors Funding & Support Grants & Donations Publication Data Request Independent Medical Education Independent Research Search -- -- Welcome to BioMarin’s Investor Relations & Media Page We’ve brought together a variety of information in one location to better assist you in your efforts to research and develop news articles and learn about our company. BioMarin Pharmaceutical Inc. was founded in 1997, and since July 1999 the company's common stock has been traded on the Nasdaq National Market under the ticker symbol BMRN. BioMarin's policy is to fully comply with all rules put forth by the Securities and Exchange Commission and the Nasdaq National Market. For misplaced stock certificates, please contact our transfer agent directly. Recent News Email Alerts Dec 21, 2020 BioMarin Announces Benefit Maintained for Over Two Years in Children with Achondroplasia Treated with Vosoritide in Phase 3 Extension Study BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that children in the open-label long-term extension of the Phase 3 study of vosoritide, an investigational, once daily injection analog... Dec 1, 2020 BioMarin to Participate in Two Upcoming Virtual Investor Conferences BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that management will participate in two upcoming virtual conferences. An audio webcast of the presentations will be available live. You... Nov 17, 2020 BioMarin and Deep Genomics to Collaborate on Advancing Programs Identified Using Artificial Intelligence BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) and Deep Genomics today announced that the companies have entered into a preclinical collaboration that will use Deep Genomics' artificial intelligence... Events & Presentations Evercore ISI 3rd Annual HealthCONx Conference Thursday, December 3, 2020 2:40pm - 3:00pm EST Piper Sandler 32nd Annual Virtual Healthcare Conference Wednesday, December 2, 2020 3:00pm - 3:25pm EST Investors/Media Welcome to BioMarin's Investor Relations & Media Page Press Releases Events & Presentations Corporate Governance Financial Information Analyst Coverage Stock Information Investor FAQs Contact Us Email Alerts Contact Us: Investor Relations Contact Information: 415-382-5731 IR@BMRN.com Media Contact Information: 415-455-7451 corporatecommunications2@BMRN.com BioMarin Compliance & Ethics Hotline Compliance is our responsibility Click here to file a report Stock Quote NASDAQ BMRN 1dy 1mo 6mo 1yr 5yr Investor Resources Request Printed Materials Email Alert Sign-Up Company Snapshot List of stockholders as of Record Date for 2020 Annual Meeting -- Navigate Our Motivation Our Treatments Our Company Investors & Media About Our History Our Products Our Pipeline Leadership Team Board of Directors Diversity & Inclusion Contact Global Contact Information Our Locations Report a Product Complaint Report Adverse Event Publication Data Request Funding & Support Connect Careers LinkedIn Facebook Instagram YouTube © 2020 BioMarin. All rights reserved. Privacy Policy Terms of Use Site Map Supplier Information Slavery Act Statement Glossary Contact Us This website uses cookies to improve website functionality. You may delete or block cookies by accessing your preferences. For more information, please see our Privacy Policy and Terms and Conditions . By using this website, you consent to our use of cookies. Accept...